BiotechTube
Neodyne Biosciences

Neodyne Biosciences

Cambridge, United States· Est.
embracescartherapy.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18M

Overview

Neodyne Biosciences is a commercial-stage medical device company focused on advanced scar management. Its flagship product, the embrace® Active Scar Defense system, is a unique, FDA-cleared device that combines proprietary Stress-Shield™ technology with medical-grade silicone to relieve tension on healing incisions, a key driver of scar formation. The product is supported by Level 1 clinical evidence from randomized controlled trials and is marketed directly to consumers and healthcare professionals for post-surgical and traumatic scar prevention. The company operates in the large and underserved dermatology and plastic surgery markets with a differentiated, clinically validated solution.

DermatologyPlastic & Reconstructive SurgeryWound Care

Technology Platform

Mechanomodulation therapy combining proprietary Stress-Shield™ technology for active tension relief with medical-grade silicone for topical scar hydration and management.

Funding History

2
Total raised:$18M
Series A$15M
Seed$3M

Opportunities

The global scar treatment market is large and growing, driven by surgical volumes and patient demand for better aesthetic outcomes.
Neodyne's FDA-cleared, clinically superior product addresses a clear gap in the standard of care, allowing for premium pricing and direct-to-consumer sales.
Expansion into adjacent wound care indications, such as diabetic wound management, represents a significant future growth vector.

Risk Factors

Key risks include challenges in driving widespread physician adoption against cheaper, established alternatives, the current lack of insurance reimbursement which limits market access, and execution risks in scaling commercial operations.
The company also faces competition from both existing OTC products and potential new entrants attracted by the market opportunity.

Competitive Landscape

Neodyne competes in the scar management market against passive silicone sheets/gels (e.g., Cica-Care, ScarAway), topical creams (e.g., Mederma), and corticosteroid injections. Its primary differentiation is its active tension-relief mechanism and Level 1 clinical data. It faces potential competition from larger medical device or pharmaceutical companies with greater resources for marketing and distribution.

More companies in Drug Delivery & Formulation →More companies in United States →